Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 7Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Stomach Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Recurrence 1Papillomavirus Infections 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1NSCLC 1Muscle Invasive Bladder Cancer (MIBC) 1

Interventions

toripalimab 1Premedication 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Tumors × toripalimab × 90 days × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡